Diabetes: Are pharmacists making an impact on patient outcomes?

Canadian Pharmaceutical Journal

Volumn 136, Issue 4, 2003, Pages 24-29

  Guirguis, Lisa M ^a,b   Johnson, Jeffrey A ^b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL ANTIDIABETIC AGENT;

BLINDNESS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; CANADA; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE; NERVE INJURY; PHARMACIST; RETINOPATHY; REVIEW; STROKE;

EID: 17444420563     PISSN: 08286914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Health Canada. Diabetes in Canada: National Statistics and Opportunities for Improved Surveillance, Prevention, and Control. Ottawa: Diabetes Division-Bureau of Cardio-Respiratory and Diabetes, Laboratory for Disease Control, Health Protection Branch, Health Canada, 1999.
2. Blanchard JF. Modeling the future health system based on diabetes surveillance data (Abstract). Canadian Diabetes Association, Halifax, NS, October 11-14, 2000.
3. Schaubel DE, Morrison HI, Desmeules M, et al. End-stage renal disease in Canada: prevalence projections to 2005. CMAJ 1999;160(11):1557-63
4. Meltzer S, Leiter L, Daneman D, et al. 1998 Clinical practice guidelines for the management of diabetes in Canada. CMAJ 1998;159;8 (Suppl)
5. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100(10):1134-46
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
7. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
8. Pyorala K, Pederson TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997;20:614-20
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13
10. McFarlane SI, Jacober SJ, Winer N, et al. Control of Cardiovascular Risk Factors in Patients With Diabetes and Hypertension at Urban Academic Medical Centers. Diabetes Care 2002;25(4):718-23
11. Saadine J, Engelgau M, Beckles GL, et al. A diabetes report card for the United States: Quality of care in the 1990s. Ann Intern Med 2002;136:565-74
12. Schapansky LM, Johnson JA, Majumdar SR, et al. The Burden of Pharmacotherapy for Patients with Type 2 Diabetes in Northern Alberta - Data from the DOVE Study. Can J Clin Pharmacol 2001;8(1):22
13. Wetzler HP, Snyder JW. Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes. Diabetes Care 2000;23(11):1637-41
14. Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001;24(8):1411-15
15. Campbell RK. DCCT opens new opportunities for pharmacists. California Pharmacist 1993; Dec:26-7
16. Berner R. Pharmacist are starting to move in on doctor's turf. The Wall Street Journal 1999.
17. Rodriguez de Bittner M, Marzella M, Erickson R. Implementation of a diabetes care program in a high volume food drug chain pharmacy. JAPhA 1999;39(2):251
18. Nau DP. Diabetes care in the Ohio valley pharmaceutical care network. JAPhA 1999;39(2):250
19. Schilling KW. Pharmacy program for monitoring diabetic patients. Am J Hosp Pharm 1977;34(11):1242-5
20. Huff PS, Ives TJ, Almond SN, Griffin NW. Pharmacist-managed diabetes education service. Am J Hosp Pharm 1983;40(6):991-4
21. Farris K, Kirking D. Assessing the quality of pharmaceutical care. II Application of concepts of quality assessment form medical care. Ann Pharmacother 1993;27:215-23
22. Basa RP, McLeod B. Evaluation of a diabetes specialty centre: structure, process and outcome. Patient Educ Couns 1995;25(1):23-9
23. Sczupak C, Conrad W. Relationships between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm 1977;34:1238-42
24. Hawkins DW, Fiedler FP, Douglas HL, et al. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 1979;36(10):1321-5
25. Brown TA, Barr JT, Schumacher GE. Outcomes assessment of pharmaceutical care in patients with diabetes. Boston, MA: Northeastern University, Bouve College of Pharmacy and Pharmaceutical Sciences, 1990.
26. Van Veldhuizen-Scott M, Wilder L, Stacey S, et al. Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes. Diabetes Educ 1995;21(2):117-23
27. Jaber LA, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43
28. Fincham JE, Lofholm PW. Saving money and lives: pharmacist care for diabetes patients. America's Pharmacist 1998;120:49-52
29. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32(6):636-41
30. Gerber RA, Liu G, McCombs JS. Impact of pharmacist consultations provided to patients with diabetes on healthcare costs in a health maintenance organization. Am J Manag Care 1998;4:991-1000
31. Cranor CW. Outcomes of the Asheville diabetes care project. Pharm Times 1998(Oct); (Supp):19-25
32. Baran R, Crumlish K, Patterson H, et al. Improving the outcomes of community-dwelling older patients with diabetes through pharmacist counseling. Am J Health Syst Pharm 1999;56:1535-39
33. Berringer R, Shibley MH, Cary CC, et al. Outcomes of a community pharmacy-based diabetes monitoring program. JAPhA 1999;39(6):791-99
34. Kelly C, Rodgers P. Implementation and evaluation of a pharmacist-managed diabetes service. J Managed Care Pharm 2000;6(6):488-93
35. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care program in a free medical clinic. Am J Med Qual 2000;15(4):137-42
36. Yanchick JK. Implementation of a drug therapy monitoring clinic in a primary-care setting. Am J Health Syst Pharm 2000;57(Suppl 4):S30-4
37. Sarkadi A, Rosenqvist U. Study circles at the pharmacy-a new model for diabetes education in groups. Patient Educ Couns 1999;37:89-96
38. Swain JH, Macklin R. Individualized diabetes care in a rural community pharmacy. JAPhA 2001;41(3):458-61
39. Guirguis L, Johnson JA, Farris KB, et al. A pilot study to evaluate the role of pharmacists certified as diabetes educators. Can J Diab Care 2001;25(4):266-76
40. Johnson JA. Self-efficacy theory as a framework for community pharmacy-based diabetes education programs. Diabetes Educ 1996;22(3):237-41
41. Glasgow RE, Osteen VL. Evaluating diabetes education: Are we measuring the most important outcomes? Diabetes Care 1992;15(10):1423-32